News

With the approval by the U.S. Food and Drug Administration on May 6 of a new antivenom to treat rattlesnake bites, the two poison control centers in Arizona are on track to begin research into the best utilization of snakebite medicines.

The project aims to train artificial intelligence to identify signs of pulmonary embolism from bedside cardiac ultrasound scans, with the goal of providing real-time assistance to health care providers.